Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
Hong Kong · Delayed Price · Currency is HKD 5.36
-0.01 (-0.19%)
Jul 31, 2026, 3:56 PM HKT
HKG:2566 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,295 | 1,855 | 1,620 | - | - | - | |
Market Cap Growth | -49.66% | 14.54% | - | - | - | - |
Enterprise Value | 679 | 1,419 | 1,716 | - | - | - |
Last Close Price | 5.36 | 7.48 | 6.49 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.54 | 12.05 | 10.98 | - | - | - |
PS Ratio | 0.89 | 1.28 | 1.11 | - | - | - |
PB Ratio | 0.71 | 1.01 | 1.00 | - | - | - |
P/TBV Ratio | 0.71 | 1.01 | 1.00 | - | - | - |
P/FCF Ratio | 5.67 | 8.12 | 19.10 | - | - | - |
P/OCF Ratio | 4.56 | 6.54 | 16.06 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.47 | 0.98 | 1.18 | - | - | - |
EV/EBITDA Ratio | 3.41 | 7.16 | 8.38 | - | - | - |
EV/EBIT Ratio | 4.32 | 9.03 | 10.27 | - | - | - |
EV/FCF Ratio | 2.97 | 6.21 | 20.24 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.10 | 0.10 | 0.08 | 0.19 | 0.29 | 0.28 |
Debt / EBITDA Ratio | 0.90 | 0.90 | 0.62 | 0.96 | 2.70 | 1.32 |
Debt / FCF Ratio | 0.79 | 0.79 | 1.52 | 1.46 | - | 15.02 |
Net Debt / Equity Ratio | -0.33 | -0.33 | -0.32 | 0.05 | 0.14 | 0.11 |
Net Debt / EBITDA Ratio | -3.10 | -3.10 | -2.55 | 0.24 | 1.29 | 0.50 |
Net Debt / FCF Ratio | -2.69 | -2.69 | -6.16 | 0.36 | -141.55 | 5.61 |
Asset Turnover | 0.65 | 0.65 | 0.85 | 1.02 | 0.94 | - |
Inventory Turnover | 1.66 | 1.66 | 1.80 | 1.74 | 1.45 | - |
Quick Ratio | 3.97 | 3.97 | 3.66 | 1.88 | 1.62 | 1.34 |
Current Ratio | 4.46 | 4.46 | 4.13 | 2.42 | 2.13 | 1.87 |
Return on Equity (ROE) | 8.74% | 8.74% | 11.47% | 14.39% | 8.07% | - |
Return on Assets (ROA) | 4.37% | 4.37% | 6.08% | 6.81% | 2.39% | - |
Return on Invested Capital (ROIC) | 11.05% | 11.41% | 13.13% | 13.48% | 5.51% | 15.36% |
Return on Capital Employed (ROCE) | 7.90% | 7.90% | 9.90% | 14.30% | 5.40% | 16.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 11.90% | 8.30% | 9.11% | - | - | - |
FCF Yield | 17.64% | 12.31% | 5.24% | - | - | - |
Dividend Yield | 1.22% | 0.85% | 0.92% | - | - | - |
Payout Ratio | 9.92% | 9.92% | - | - | 20.04% | - |
Buyback Yield / Dilution | -20.16% | -20.16% | -2.11% | - | - | - |
Total Shareholder Return | -18.94% | -19.31% | -1.20% | - | - | - |